Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Go, S.-I. | - |
dc.contributor.author | Lee, S.-C. | - |
dc.contributor.author | Bae, W.K. | - |
dc.contributor.author | Zang, D.Y. | - |
dc.contributor.author | Lee, H.W. | - |
dc.contributor.author | Jang, J.S. | - |
dc.contributor.author | Ji, J.H. | - |
dc.contributor.author | Kim, J.H. | - |
dc.contributor.author | Park, S. | - |
dc.contributor.author | Sym, S.J. | - |
dc.contributor.author | Yang, Y. | - |
dc.contributor.author | Jeon, S.Y. | - |
dc.contributor.author | Hwang, I.G. | - |
dc.contributor.author | Oh, S.Y. | - |
dc.contributor.author | Kang, J.H. | - |
dc.date.accessioned | 2021-09-17T03:40:25Z | - |
dc.date.available | 2021-09-17T03:40:25Z | - |
dc.date.issued | 2021-11 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.issn | 1879-0852 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/49388 | - |
dc.description.abstract | Background: The efficacy of modified FOLFIRINOX (mFOLFIRINOX) as a second-line chemotherapy treatment for metastatic pancreatic adenocarcinoma (mPAC), remains unclear. This multi-center randomised phase III trial aimed to elucidate the efficacy of mFOLFIRINOX as a second-line chemotherapy treatment for mPAC patients with good performance status. Patients and methods: Eighty mPAC patients (age, 19–75 years) refractory to first-line gemcitabine-based chemotherapy were randomly selected to receive mFOLFIRINOX or S-1. mFOLFIRINOX comprised oxaliplatin (65 mg/m2), irinotecan (135 mg/m2), and leucovorin (400 mg/m2) on day 1 and continuous 5-FU infusion (1000 mg/m2) over 24 h on days 1–2 every 2 weeks. S-1 comprised body surface area-dependent oral S-1, divided into two doses per day on days 1–28 every 6 weeks. Results: Overall survival was the primary endpoint. The objective response and disease control rates were higher in the mFOLFIRINOX than in the S-1 group (15% versus 2%; p = .04 and 67% versus 37%; p = .007). The median progression-free survival rates were 5.2 and 2.2 months in the mFOLFIRINOX and S-1 groups, respectively (adjusted hazard ratio [HR]: .4; 95% confidence interval [CI]: .2-.6; p < .001). The median overall survival rates were 9.2 and 4.9 months in the mFOLFIRINOX and S-1 groups, respectively (adjusted HR: .4; 95% CI: .2–.7; p = .002). Grade 3-4 adverse events occurred in 56% and 17% of the patients in the mFOLFIRINOX and S-1 groups, respectively (p < .001). Conclusion: Administration of mFOLFIRINOX as a second-line chemotherapy treatment for mPAC patients refractory to gemcitabine-based chemotherapy resulted in increased survival rates than S-1 treatment alone. © 2021 Elsevier Ltd | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier Ltd | - |
dc.title | Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3) | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.ejca.2021.08.002 | - |
dc.identifier.bibliographicCitation | European Journal of Cancer, v.157, pp 21 - 30 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000701900000003 | - |
dc.identifier.scopusid | 2-s2.0-85113819921 | - |
dc.citation.endPage | 30 | - |
dc.citation.startPage | 21 | - |
dc.citation.title | European Journal of Cancer | - |
dc.citation.volume | 157 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Gemcitabine | - |
dc.subject.keywordAuthor | Modified FOLFIRINOX | - |
dc.subject.keywordAuthor | Pancreatic neoplasms | - |
dc.subject.keywordAuthor | Randomised controlled trial | - |
dc.subject.keywordAuthor | S-1 | - |
dc.subject.keywordAuthor | Second-line chemotherapy | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | MONOTHERAPY | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | LEUCOVORIN | - |
dc.subject.keywordPlus | IRINOTECAN | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.